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Key Points 
1. Breast cancer patients have a risk of VTE equivalent to 6% a year whilst undergoing 
chemotherapy and in the month following treatment. 
2. Tamoxifen is associated with a risk of VTE equivalent to 2% a year, which is 4-times higher 
than the risk before commencing therapy. 
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Abstract 
 
Breast cancer patients are at increased risk of VTE, particularly in the peri-diagnosis period. 
However, no previous epidemiological studies have investigated the relative impact of breast cancer 
treatments in a time-dependent manner. We aimed to determine the impact of breast cancer stage, 
biology and treatment on the absolute and relative risks of VTE, using several recently linked data 
sources from England. Our cohort comprised 13,202 breast cancer patients from the Clinical Practice 
Research Datalink (linked to Hospital Episode Statistics and Cancer Registry data), diagnosed 
between 1997 and 2006 with follow-up continuing to the end of 2010.  Cox regression analysis was 
performed to determine which demographic, treatment-related and biological factors independently 
affected VTE risk. Women had an annual VTE incidence of 6% whilst receiving chemotherapy which 
was 10.8-fold higher (95% CI, 8.2 to 14.4; absolute risk (AR) =59.6 per 1000 person-years) than 
women who did not receive chemotherapy. Following surgery the risk was significantly raised in the 
first month (HR=2.2; 95% CI 1.4 to 3.4; AR=23.5; reference group, no surgery), but it was not raised 
subsequent to this.  Risk of VTE was noticeably higher in the 3-months following initiation of 
Tamoxifen compared with the risk before therapy (HR=5.5; 95% CI 2.3 to 12.7; AR=24.1), however 
commencement of aromatase inhibitors was not associated with VTE (HR=0.8; 95% CI 0.5 to 1.4; 
AR=28.3). In conclusion, women receiving chemotherapy for breast cancer have a clinically 
important risk of VTE, whilst an increased risk of VTE immediately following endocrine therapy is 
restricted to Tamoxifen. 
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Introduction 
 
Women with breast cancer have a 3-4 fold increased risk of VTE compared to women of an 
equivalent age without cancer.1,2 As breast cancer is the most common cancer worldwide,3 this 
equates to a substantial impact of breast cancer-related VTE for patients and medical resources. 
Breast cancer associated VTE accounts for approximately 17% of cancer-related VTEs presenting to 
anticoagulation clinics.4  It is also associated with increased disease recurrence,5 but more 
importantly reduced survival,5,6 among a patient group for whom prognosis is otherwise 
comparatively good. 
Previous cohort studies have identified several risk factors for VTE in breast cancer patients 
including metastatic disease,2,7,8 chemotherapy2,8,9 and Tamoxifen treatment.10 A recent systematic 
review demonstrated that on average, breast cancer patients selected because they had either 
metastatic disease or were  undergoing surgery or chemotherapy had a 10-fold increase in VTE risk 
compared to the breast cancer population as a whole.11 While these studies go some way to 
highlighting which groups are at highest risk of VTE, none have comprehensively assessed the 
relative importance of cancer treatments and biology in influencing VTE risk using prospectively 
gathered data.  
Identifying combinations of between and within patient factors would allow us to develop 
algorithms to guide thromboprophylaxis in the setting of breast cancer. Guidelines issued by the 
National Comprehensive Cancer Network (NCCN) emphasise that general use of 
thromboprophylaxis in patients receiving chemotherapy remains controversial and that more data 
are needed before risk-adjusted thromboprophylaxis can be routinely introduced in clinical 
practice.12 Guidelines from the American College of Chest Physicians (ACCP) also advise against 
routine prophylaxis for cancer outpatients unless they have additional risk factors including 
previous thrombosis, immobilisation, hormonal therapy and angiogenesis inhibitors, a 
recommendation based on low grade evidence.13 In both instances, there is limited guidance for 
specific cancer types (including breast) between which the influence of other risk factors could vary 
substantially.   Identifying these patients most at risk is problematic owing in part to the absence of 
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precise and accurate data on absolute risks of VTE during specific times of their disease course. We 
have addressed this by ascertaining the  incidence rate of VTE in relation to tumour biology (cancer 
grade and stage), intrinsic patient factors (age, body mass index (BMI) and  comorbidity) and cancer 
treatments (surgery, chemotherapy and endocrine therapy) using four recently linked healthcare 
databases from the UK.   
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Methods 
Patients and data sources 
We utilised data from four linked healthcare sources. The Clinical Practice Research Datalink (CPRD) 
is a prospectively gathered, anonymised primary care database using data from more than 600 GP 
practices in the UK from 1987 onwards. It provides all recorded primary care data on patients 
including clinical diagnoses and prescriptions and is known to be broadly representative of the UK 
population in terms of age, sex, socioeconomic and geographic distribution.14 Hospital Episodes 
statistics (HES) is a secondary care database containing data for all hospitalisations in England, 
including primary and secondary discharge diagnoses and inpatient procedures. Information on 
cancer diagnoses was obtained from the National Cancer Intelligence Network (NCIN) which 
processes data supplied by all regional cancer registries in the UK. 15  Two related but separate 
databases make up the cancer registry data; the Merged Cancer Registry data (from English 
registries only) and the Office of National Statistics (ONS) minimum cancer dataset. Detailed 
information on specific data items collected by cancer registries in England for breast cancer 
patients over the period of this study (1997 to 2006), along with the completeness of recording for 
each of the TNM components we used to define cancer stage can be found elsewhere.16 Finally, we 
used death certificate data from the ONS which provides information on dates and underlying causes 
of death. The present analysis is based on patients from approximately 50% of CPRD practices in 
England for whom data linked to the HES, NCIN and ONS data sources are available from April 1997 
onwards. The study received approval from the CPRD Independent Scientific Advisory Committee 
(protocol no. 10_091). 
We selected all patients who had a first breast cancer diagnosis (ICD-10 code C50) between 1st April 
1997 and 31st December 2006. Patients were followed up until they developed a VTE event, died, left 
a participating GP practice or 31st December 2010, whichever was earliest. The earliest recorded 
date in the cancer registry data was used to determine date of cancer diagnosis.  Patients were 
excluded if they were: 
 Male 
 Under 18 years of age 
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 Not in a linked general practice. 
 Diagnosed with breast cancer outside of the CPRD and HES registration periods 
 Diagnosed in the first year of registration at a participating practice. 
 Had a VTE prior to first cancer diagnosis 
Risk Factors  
Cancer stage and grade at diagnosis were obtained from the cancer registry database.  Where 
known, we classified stage as either “local disease” (confined to the breast), “regional disease” 
(axillary lymph node involvement), or “distant metastases” (any evidence of distant metastases). 
Conversion from TNM staging into these summary stages was carried out according to the algorithm 
designed by Ording et al.17 Cancer treatments were defined on the basis of an associated OPCS-4 
code for chemotherapy and surgery using the hospital admissions data. Surgery codes were specific 
to procedures used in the treatment of breast cancer. For chemotherapy, events were frequently 
recorded as a series of day case or outpatient procedures and were considered as part of the same 
course of treatment when occurring within 28 days of each other. Broad OPCS-4 codes for 
chemotherapy were used, limiting our potential to study specific chemotherapy regimens. We 
distinguished endocrine treatment with Tamoxifen from the newer aromatase inhibitors (AI), both 
of which were obtained from the GP prescription record. We assumed that women without 
endocrine prescriptions had oestrogen receptor negative breast cancer. BMI was  determined from 
GP records based on the most recent recording prior to cancer diagnosis, whilst GP records were 
also used to calculate an individual comorbidity score (Charlson index but ignoring the breast cancer 
diagnosis which was universal in our cohort) for each patient (coded as 0,1-3,≥4).18  
Outcome 
Primary care (CPRD) medical diagnoses were recorded using Read codes and secondary care (HES) 
diagnoses using ICD-10 codes. A VTE event was confirmed when a medical code for venous 
thromboembolism (ICD 10; I26, I80-I82) in either or both the CPRD and HES was supported by 
either an anticoagulant prescription or medical code providing evidence of anticoagulation if either 
were recorded between 15 days before and 90 days after the VTE event date, or if death occurred 
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within 30 days of the event. Additionally, an underlying cause of death of VTE was included as 
evidence of a valid VTE event. Only the first VTE event following the cancer diagnosis was 
considered as follow-up would cease at this time, therefore all subsequent VTE events were ignored. 
This algorithm for defining VTE has been previously validated using primary care data alone, 
although this validation was carried out in women who developed VTE following oral contraceptive 
use rather than in women with breast cancer.19 
Statistical methods 
Absolute risks of VTE (per 1000 person years) were calculated on the basis of all risk factors listed 
above by dividing the number of people with VTE by the person-time at risk.  To establish the 
independent effects of these risk factors, Cox regression was used to obtain adjusted hazard ratios.  
BMI, comorbidity, cancer stage and cancer grade were all treated as time-independent covariates 
whilst the effects of cancer treatments were allowed to vary by time. Each variable was examined on 
its own within the breast cancer cohort, and then adjusted for all other variables in the model 
regardless of their own significance. Adjusted hazard ratios were presented in the results text. 
For surgery and chemotherapy, we then assessed the absolute VTE risk i) before treatment, ii) 
during treatment, and iii) in monthly periods post treatment. For endocrine treatment, we assessed 
the risk i) before therapy, ii) in the three month interval following the initial prescription and iii) 
subsequent follow-up time, periods selected to account for the fact that endocrine therapy is usually 
administered continuously for a minimum of 5 years. For all treatment variables patients who did 
not undergo the treatment comprised the reference category. Whilst date of cancer diagnosis was 
always used to denote study entry, calendar time was used as the timescale for our analysis so that 
both the unadjusted and adjusted hazard ratios would account for any temporal confounding. 
In subsequent analyses we looked at the joint relationship between surgery and chemotherapy, to 
account for the fact that chemotherapy often takes place during the time in which women are 
recovering from surgery. By assuming a long period of excess VTE risk following surgery or 
chemotherapy completion (3 months), this allowed us to explore absolute risks in the absence of 
potential carry-over effects from the other treatment.  We also looked at the interaction between 
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cancer stage and the effects of surgery and chemotherapy.  There were missing data in our cohort for 
cancer stage, grade and body mass index. We accounted for these missing data by creating a category 
comprising women with missing data. When analyses were repeated using multiple imputation by 
chained equations to impute missing values, results were very similar. All analyses used Stata 
version 13 (Statacorp, College Station, Texas).  
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Results 
 
Patient characteristics 
A total of 13,202 women were diagnosed with breast cancer between 1997 and 2006 (Table 1). 
Women were a median age of 62 years at cancer diagnosis (IQR, 52 to 74 years). A total of 4% had 
metastatic disease at diagnosis and 38% had local disease (with stage unknown for 36% of women). 
77% of the sample underwent surgery at some point following cancer diagnosis, 21% underwent 
chemotherapy and 82% were prescribed endocrine therapy. First surgery occurred on average 17 
days (IQR, 0 to 31) after cancer diagnosis. Among women who had primary surgery for breast 
cancer, chemotherapy began an average of 52 days (IQR 33 to 105) after surgery. The median 
follow-up time from diagnosis was 5.3 years (IQR 2.8, 8.0 years). VTE occurred in 611 cases among 
72,596 person-years of follow-up corresponding to a rate of 8.4 per 1000 person years (95% 
confidence Interval, CI, 7.8-9.1). This rate was 3.5 times (95% CI, 3.2 to 3.9) higher than in age 
matched controls as shown in our previous paper from this cohort.1  The rate of VTE in breast cancer 
patients increased over the time period of the study from 5.4 per 1,000 person-years (3.6 to 8.2) for 
women with breast cancer diagnosed in 1997 to 10.5 per 1,000 person-years (8.5 to 13.2) for 2005. 
Of the VTE events, there were 273 women who developed PE either with or without DVT, 314 who 
developed DVT alone and 24 other thrombosis events. In most instances, the type of DVT was not 
specified (n=175), where this was specified 13 out of 139 events were upper extremity events. 
Demographic and tumour related factors and risk of VTE 
Increased age and BMI were significant predictors of VTE (Table 2).  VTE risk increased with age, 
with women aged 80 years or over at diagnosis having five times the risk  compared with younger 
women (adjusted HR=5.0; 95% CI, 3.0-8.2; absolute rate (AR), 14.9 per 1,000 person-years).  BMI 
had a similarly large influence on VTE risk, with the highest rate in women who were morbidly 
obese (BMI≥40kg/m2) (HR=3.0; 95% CI, 2.1-4.4; AR, 16.5; reference group, BMI 18.5-25.0 kg/m2). 
Whilst the rate of VTE was higher in women with metastatic cancer (18.2 per 1,000 person-years) 
compared to those with local disease (6.8 per 1,000 person-years), this was in part due to the higher 
mean age among women with metastatic disease (66.3 years, SD 15.1) compared with local disease 
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(61.3 years, SD 12.8) and that more women with metastatic disease underwent chemotherapy 
(27.0%) than with local disease (15.2%). When these two variables alone were adjusted for the 
hazard ratio for metastatic disease decreased from 2.5 (95% CI, 1.6-4.0) in the univariable model to 
1.5 (95% CI, 1.0-2.5). Similarly, a higher absolute rate of VTE among women with a high Charlson 
score (≥4), could be largely accounted for by the higher mean age among women with a Charlson 
score ≥4 (72.0 years, SD 13.0) than those with a Charlson score of 0 (60.6 years, SD 14.5).  
 Surgery and risk of VTE 
Surgery in this cohort took the form of either mastectomy (with 9.1% having immediate 
reconstruction) or a breast-conserving procedure. When other factors were accounted for a 
significantly increased risk compared with those not undergoing surgery only existed in the first 
month following discharge from the surgical admission (HR=2.2; 95% CI, 1.4 to 3.4; absolute rate 
=23.5 per 1,000 person-years) (Table 2). Rates of VTE following surgery did not vary by stage 
(monthly rates ranging from 17 to 28 per 1,000 person-years; Table 3; Test for interaction between 
surgery and stage, P=0.15). 
Chemotherapy and risk of VTE 
Women who underwent chemotherapy had very high absolute risks of VTE both during 
chemotherapy and in the month following cessation of therapy (both >50 per 1,000 person-
years)(Table 2). The adjusted hazard ratios compared to no chemotherapy were 10.8 (8.2 to 14.4)  
during chemotherapy and 8.4 (4.9-14.2) in the month afterwards. The risk of VTE remained high in 
the second month following completion of therapy, but by 3 months the risk had reverted to that 
before treatment (Figure 1). The adjusted hazard ratio during chemotherapy compared to time 
before chemotherapy in the same patients was 6.6 (95% CI, 4.3 to 10.1). The effect of stage on risk of 
VTE was more pronounced during follow-up time outside of chemotherapy (HR=2.5 for metastatic 
disease; 1.6 to 4.2), with a significant interaction between stage and chemotherapy treatment 
(P=0.004)(Table 3).   
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Independent effects of stage, surgery and chemotherapy   
When looking at chemotherapy and surgery jointly, the absolute risk of VTE was particularly high 
when surgery took place in the 2 month chemotherapy recovery period, however, this was based on 
a small number of events and as such the confidence interval was wide (AR=92.1; 38.3 to 
221.2)(Table 4).  
Endocrine therapy and risk of VTE  
In the three months following commencement of endocrine therapy, the risk of VTE was more than 
double the risk in those who did not receive endocrine therapy (HR=2.4; 95% CI 1.7 to 3.4; 
AR=27.7)(Table 2). No increased risk was observed beyond three months of therapy (HR=0.9; 95% 
CI 0.7 to 1.1; AR=7.0).  
When absolute risks were explored on the basis of type of endocrine therapy there were important 
differences between Tamoxifen and AIs (Table 5). VTE risk increased more than 5-fold in the 3 
months following commencement of therapy among women who received Tamoxifen only (HR=5.5; 
95% CI 2.3 to 12.7; AR=24.1; reference category – risk before commencing Tamoxifen). After 3 
months a non-significant 2-fold increase in risk remained (HR=1.9; 95% CI 0.9 to 4.3; AR=5.2). 
Specific adjustment for chemotherapy (which occurred frequently in the cohort time prior to 
Tamoxifen) accounted for most of the difference between the univariable and multivariable results 
(HR=1.1 vs. HR=1.9). In contrast to Tamoxifen, among those receiving an AI only, there was no 
increase in risk in the three months after starting therapy (AR=0.8; 95% CI 0.5 to 1.4; AR=28.3; 
reference category – risk before commencing AIs). Furthermore, we found that among women who 
switched to an AI after initially taking Tamoxifen, the absolute risk following commencement of the 
AI was similar to that in the period before commencement of the AI (subsequent time for Tamoxifen, 
Table 5). 
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Discussion 
 
It is known that women with breast cancer have a 3.5 fold increased risk of VTE compared to women 
of a similar age without cancer.1,2  A risk of this magnitude would not justify continuous VTE 
prophylaxis and thus it becomes important to identify subgroups of patients and time where the risk 
is highest. Using routinely available data from primary care, secondary care and UK cancer registries 
we report high risks of VTE among women undergoing chemotherapy and in the first three months 
of treatment with Tamoxifen.  During chemotherapy the risk of VTE was raised more than 10-fold 
and this risk remained high in the 2-months following completion of treatment.   Among women who 
commenced Tamoxifen, the risk of VTE was 5-times higher than it was in the period before 
commencing therapy. We also observed a doubling of rates of VTE in women with breast cancer over 
the 10-year period of the study. This is consistent with reports of an increase in risk of cancer-
associated VTE over time in both this and other populations, a trend which may be due to either 
more aggressive cancer treatments or ascertainment resulting from greater knowledge of the link 
between cancer and thrombosis. 1,20–22 
This report contained both absolute risks (unadjusted) and adjusted hazard ratios. Interpretation of 
absolute risks and associated unadjusted hazard ratios may be more useful in terms of clinical 
decision making if made on the basis of a single factor. However, we observed that unadjusted and 
adjusted hazard ratios were always similar except in two specific instances where highlighted 
(chemotherapy and stage; age and comorbidity). In a stratified analysis involving stage and 
chemotherapy, we reported a much higher risk of VTE with metastatic disease compared with local 
disease within time periods not influenced by chemotherapy (unadjusted HR of 3.2 and adjusted HR 
of 2.5). However, during chemotherapy and immediately afterwards, rates of VTE were high 
regardless of stage although these estimates were based on small event numbers. 
Our observed rate of 8.4 per 1000 person years was similar to that reported by Chew et al. in the 
largest study carried out to date on VTE risk in breast cancer.7 In our study, we were also able to 
look at several risk factors absent from the Californian study including detailed and accurate 
recording of chemotherapy treatment and use of endocrine therapy, as well as BMI. Furthermore, 
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our study contained a longer average follow-up duration (5.5 years) than both the Californian and 
other comparable studies2,8,9 and we were able to assess the effects of surgery and chemotherapy in 
a time dependent manner in a way which has evaded previous research. 
Chemotherapy is known to be an important risk factor for VTE in cancer patients. Previously in 
relatively small cohorts of women receiving chemotherapy for breast cancer, risks of VTE have 
ranged from 5.5 to 8.0% among women with loco-regional disease5,23,24 and from 4.4 to 17.7% in 
women with metastatic disease.23,25,26   Using data on 2,773 women undergoing chemotherapy for 
breast cancer, we reported  a risk of VTE which was the equivalent of 5-6 percent a year both during 
chemotherapy and in the month after therapy (with 3.7% of women undergoing chemotherapy 
developing a VTE either during treatment or the 3 months following completion). The risk during 
therapy was 6.6-times higher than in the same women before therapy when adjusted for other 
treatment factors. A validated risk prediction tool has been developed to determine which patients 
undergoing chemotherapy are at highest risk and could therefore benefit from prophylaxis.27 
However, neither that study nor a more recent extension28 of the score was able to demonstrate the 
periods of highest risk for patients, and since both required informed consent they were likely to 
exclude those with the poorest performance status.  
We found that the risk of VTE was around 2-fold higher following discharge after surgery; however 
the risk was only increased for the month following surgery once other factors were accounted for 
and the magnitude of the increase was much less than following chemotherapy. This smaller effect 
may in part reflect the minimal-invasiveness of breast cancer surgery which does not penetrate body 
cavities, particularly in an era when breast reconstruction was less frequently performed. Whilst 70-
80% of UK breast surgeons in this era prescribed anticoagulant thromboprophylaxis to breast 
cancer patients undergoing surgery, our increased risk was observed in the time following discharge 
in which thromboprophylaxis is not usually administered.29 Despite limited numbers, we 
demonstrate a particularly increased risk of VTE associated with surgery following chemotherapy. 
As neoadjuvant chemotherapy is increasingly being used, that has important implications for 
surgical thromboprophylaxis in the neoadjuvant setting.  
15 
 
 
 
Tamoxifen is a widely recognised risk factor for VTE. The magnitude of increase in risk of VTE we 
observed following commencement of Tamoxifen is comparable with studies comprising women 
with early stage breast cancer reported between 1989 and 1999, which report an excess risk of VTE 
events in women receiving Tamoxifen of between 1.5-fold and 7-fold.30 Our results are also 
concordant with those from a large cohort of women with early stage breast cancer from Denmark 
where Tamoxifen treated women had a 3.5-fold higher risk of VTE than women receiving other 
treatments.10 Previous research has found the influence of Tamoxifen on risk of VTE to attenuate 1-2 
years after  commencement of therapy,10,31 possibly suggesting an adaptation of the haemostatic 
system to the procoagulant effects of Tamoxifen. This is the first study to demonstrate that the 
prothrombotic effects of Tamoxifen are noticeably reduced after only 3 months of treatment.   More 
recently, AIs have become more commonly used however the impact of these on the risk of VTE is 
less clearly established.32  In observational research such as this, a direct comparison of VTE risks 
between Tamoxifen and AIs is complicated by the fact that prescriptions for AIs were until quite 
recently limited to higher risk patients because of the high cost of on-patent drugs, as evidenced by 
the very high baseline rate of VTE among this group. In addition, patients receiving AIs are likely to 
be an older group, as AI use, unlike Tamoxifen, is limited to post-menopausal women.   
A limitation of our study is that whilst we had a large sample size overall, looking at risks on the 
basis of more intricate combinations of risk factors was hampered by small numbers of events.  For 
instance, whilst we found the risk of VTE was high in women undergoing surgery shortly after 
chemotherapy, only five VTE events occurred during this period and hence the confidence interval 
around the absolute risk was wide. Our results also need to be interpreted in light of the fact that 
data on cancer stage could not be determined for around one third of our sample. This reflects our 
reliance on routinely collected data where this level of recording is standard. However, among those 
who did have data on stage, five-year survival rates among women with localised (88%) and 
metastatic disease (27%) in our study were consistent with published data from the US population.33 
As we have previously acknowledged, our algorithm for defining VTE was not validated specifically 
in cancer patients and would not capture anticoagulant prescriptions emanating from secondary 
care.1 However, the usual requirement is for cancer patients to receive continuous anticoagulant 
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therapy for a minimum of 3 months following the primary VTE and such prescriptions would be 
captured in primary care. Furthermore, previous studies using administrative data have relied solely 
on physician coding of VTE without requiring evidence of anticoagulation.7,8,10,34 Previously, our 
algorithm was shown to have a positive predictive value of 84% when using VTE codes from 
primary care only.19 Whilst this is higher than studies which have relied solely on administrative 
codes for defining VTE,35–37 it could still indicate that some of our VTE cases are liable to be false 
positives, which if greater than the number of VTE cases not captured by our algorithm would result 
in a slight overestimation in absolute rates of VTE in each exposure category. A Further limitation of 
our work includes the lack of data on thromboprophylaxis occurring during inpatient episodes, 
whether this be for cancer treatments (e.g. surgery) or complications of the malignancy. However, 
thromboprophylaxis specifically for systemic cancer treatment was rare based on a questionnaire 
survey conducted during this study period.38 In addition, ambulatory thromboprophylaxis with 
aspirin is likely to have been obtained predominantly over the counter for the current study cohort 
(who had a median age of 62 years) so this would also not be reliably captured via our primary care 
data. Finally, we relied on adjustment for Charlson index to account for any confounding due to 
underlying health status. Whilst one could argue that this would be less exhaustive than adjusting 
for specific health indices which influence VTE risk, we found that adjusting for Charlson score had 
very minimal impact on the effect sizes observed for other variables of interest. Consequently, we 
believe it is very unlikely that adjustment for additional health-related variables would explain much 
of the large increase in risk we observed following chemotherapy and Tamoxifen initiation unless 
the Charlson score was to be a particularly poor indicator of morbidity which has been proved not to 
be the case.39 
Breast cancer is the most common cancer worldwide, with women in the UK specifically having a 1 
in 8 lifetime risk of developing breast cancer.40 The financial and human impact of breast cancer-
related VTE therefore means that identifying women who are most at risk and would potentially 
benefit from prophylactic intervention is vital. Our data was able to address this by demonstrating  
that whilst chemotherapy is known to increase the risk of VTE in both breast and other cancers,  this 
risk remained high for two months following completion of the final course of therapy, and that this 
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risk may be increased further  where it is commenced soon after surgery. Such detail can 
complement the recent ACCP and NCCN guidelines recommending prophylaxis for higher-risk 
outpatient cancer patients.12,13 Speculation as to the absolute VTE risk above which prophylaxis is 
advised needs to take into account the harms (in particular bleeding) as well as benefits of 
prolonged anticoagulation, which is beyond the scope of the present work. Further observational 
research on this topic would benefit from the inclusion of information on laboratory data (e.g. 
haemoglobin and platelet counts) as well as more novel biomarkers which are not universally 
available in studies using electronic data recorded for administrative purposes. An attractive feature 
of our study, however, is that risks are presented based on easily ascertainable yet time-dependent 
risk factors, which we believe could form the basis of selection of appropriate patients for future 
randomised trials. Future research should focus on the development of prognostic models to identify 
specific women with breast cancer for whom the benefits of prophylactic intervention would 
outweigh the harms. 
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Table 1: Characteristics of breast cancer patients 
 
  Number of patients Number with VTE 
    N % VTE %  with VTE 
Total   13,202   611   
Cancer stage Local disease 5,037 38.2 214 4.3 
 
Regional disease 2,961 22.4 161 5.4 
 
Distant metastases 470 3.6 21 4.5 
  Unknown 4,734 35.9 215 4.5 
Grade Well differentiated 1,681 12.7 71 4.2 
 Moderately differentiated 4,232 32.1 196 4.6 
 Poorly differentiated 3,024 22.9 166 5.5 
 Unknown 4,265 32.3 178 4.2 
Age (years) <40 715 5.4 21 2.9 
 
40-49 2,030 15.4 63 3.1 
 
50-59 3,262 24.7 108 3.3 
 
60-69 2,973 22.5 179 6.0 
 
70-79 2,407 18.2 158 6.6 
  ≥80 1,815 13.8 82 4.5 
Comorbidity 0 6,987 52.9 295 4.2 
 
1 to 3 5,860 44.4 293 5.0 
  ≥4 355 2.7 23 6.5 
Body mass  Underweight (<18.5) 192 1.5 4 2.1 
Index (kg/m2) Ideal (18.5-24.9) 3,099 23.5 93 3.0 
 
Overweight (25.0-29.9) 2,520 19.1 148 5.9 
 
Obese (30.0-39.9) 1,119 8.5 73 6.5 
 
Morbidly obese (≥40.0) 440 3.3 38 8.6 
  Missing 5,832 44.2 255 4.4 
Surgery No 3,093 23.4 104 3.4 
  Yes 10,109 76.6 507 5.0 
Chemotherapy No 10,429 79.0 422 4.1 
  Yes 2,773 21.0 189 6.8 
Endocrine No 2,323 17.6 87 3.7 
 therapy Yes 10,879 82.4 524 4.8 
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Table 2: Rates of VTE in relation to potential risk factors  
 
 
  
 
 Absolute rates Univariable Cox model Multivariable Cox modela 
   Events Person-timeb Rate
c 95% CI HR 95% CI HR 95% CI 
Stage Local disease (n=5,037) 214 31.4 6.8 6.0 7.8 Reference 
 
  Reference 
  
 
Regional disease (n=2,961) 161 16.3 9.9 8.5 11.6 1.4 1.2 1.8 1.2 0.9 1.4 
 
Distant Metastases (n=470) 21 1.2 18.2 11.9 28.0 2.5 1.6 4.0 1.5 1.0 2.4 
  Unknown (n=4,734) 215 23.8 9.0 7.9 10.3 1.3 1.1 1.6 1.2 0.9 1.4 
Grade Well differentiated (n=1,681) 71 11.1 6.4 5.1 8.1 Reference 
 
  Reference 
  
 
Moderately differentiated (n=4,232) 196 25.1 7.8 6.8 9.0 1.3 1.0 1.7 1.1 0.8 1.5 
 
Poorly differentiated (n=3,024) 166 16.1 10.3 8.9 12.0 1.2 0.9 1.6 1.1 0.8 1.4 
 Unknown (n=4,265) 178 20.3 8.7 7.6 10.1 1.6 1.2 2.1 1.3 1.0 1.7 
Surgery No surgery (n=3,093) 104 11.5 9.0 7.4 10.9 Reference 
 
  Reference 
  
 
Before surgery 13 1.5 8.7 5.1 15.0 0.9 0.5 1.6 0.7 0.4 1.2 
During surgery hospitalisation  3 0.2 17.9 5.8 55.5 1.7 0.6 5.5 1.5 0.5 4.9 
 
1st month following discharge 26 1.1 23.5 16.0 34.5 2.4 1.6 3.8 2.2 1.4 3.4 
 
2nd month following discharge 24 1.0 24.3 16.3 36.2 2.4 1.5 3.8 1.4 0.9 2.2 
 
3rd month following discharge 12 1.0 12.6 7.2 22.2 1.2 0.7 2.2 0.6 0.3 1.1 
 Subsequent time 429 56.3 7.6 6.9 8.4 0.9 0.7 1.1 1.0 0.8 1.3 
Chemotherapy No chemotherapy (n=10,429) 422 57.1 7.4 6.7 8.1 Reference 
 
  Reference 
  
 
Before chemotherapy 31 2.7 11.7 8.2 16.6 1.5 1.0 2.1 1.6 1.1 2.4 
 
During chemotherapy 77 1.3 59.6 47.7 74.5 7.7 6.0 9.8 10.8 8.2 14.4 
 
1st month following completion 15 0.3 51.6 31.1 85.5 6.5 3.9 10.9 8.4 4.9 14.2 
 
2nd month following completion 8 0.2 33.1 16.6 66.3 4.0 2.0 8.1 4.5 2.2 9.3 
 
3rd month following completion 3 0.2 13.5 4.4 41.9 1.8 0.6 5.5 2.0 0.6 6.3 
 Subsequent time 55 10.8 5.1 3.9 6.7 0.7 0.5 0.9 1.1 0.8 1.5 
Endocrine therapy No endocrine therapy (n=2,323) 87 9.8 8.9 7.2 11.0 Reference 
 
  Reference 
  
 
Before endocrine therapy 54 3.0 17.8 13.7 23.3 1.9 1.3 2.6 1.2 0.8 1.7 
 
First 3 months of endocrine therapy 69 2.5 27.7 21.9 35.0 2.9 2.1 4.0 2.4 1.7 3.4 
 Subsequent time 401 57.3 7.0 6.3 7.7 0.8 0.6 1.0 0.9 0.7 1.1 
Body mass  Underweight (<18.5)(n=192) 4 1.1 3.8 1.4 10.1 0.7 0.3 2.0 0.7 0.3 1.9 
Index (kg/m2) Ideal (18.5-24.9)(n=3,099) 93 18.3 5.1 4.2 6.2 Reference 
  
Reference 
   Overweight (25.0-29.9)(n=2,520) 148 14.7 10.1 8.6 11.8 2.0 1.5 2.6 1.8 1.4 2.4 
 Obese (30.0-39.9)(n=1,119) 73 6.4 11.4 9.1 14.3 2.2 1.6 3.0 2.1 1.6 2.9 
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 Morbidly obese (≥40.0)(n=440) 38 2.3 16.5 12.0 22.7 3.2 2.2 4.7 3.0 2.1 4.4 
  Missing (n=5,832) 255 29.9 8.5 7.6 9.7 1.6 1.3 2.0 1.5 1.2 1.9 
Age (years) <40 (n=715) 21 4.1 5.1 3.4 7.9 Reference 
 
  Reference 
  
 
40-49 (n=2,030) 63 12.7 5.0 3.9 6.3 1.0 0.6 1.7 1.1 0.7 1.8 
 
50-59 (n=3,262) 108 20.7 5.2 4.3 6.3 1.1 0.7 1.7 1.3 0.8 2.1 
 
60-69 (n=2,973) 179 17.7 10.1 8.7 11.7 2.1 1.3 3.3 2.9 1.8 4.6 
 
70-79 (n=2,407) 158 11.9 13.3 11.4 15.5 2.7 1.7 4.2 4.2 2.6 6.7 
 
≥80 (n=1815) 82 5.5 14.9 12.0 18.4 2.9 1.8 4.7 5.0 3.0 8.2 
Charlson index 0 (n=6,987) 295 37.5 7.8 7.1 8.8 Reference    Reference   
 1 to 3 (n=5,860) 293 33.6 8.7 7.8 9.8 1.1 1.0 1.4 1.0 0.8 1.1 
 ≥4 (n=355) 23 1.5 15.4 10.2 23.1 2.1 1.4 3.3 1.3 0.9 2.1 
a Hazard ratios adjusted for all other variables in table. All variables were fitted using the categorisation displayed in the table (i.e. age group as a 6-level non-ordered categorical variable). 
b person-years/1,000 
c per 1,000 person-years 
Subsequent time refers to the time and rate after the procedure until the completion of follow-up. 
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Table 3: Rates of VTE by stage stratified by treatment 
       
Univariable Multivariabled 
    Events Time (1000s years) Rate 95% CI HR 95% CI HR 95% CI 
No active therapya Local disease 160 29.99 5.3 4.6 6.2 Reference 
  
Reference 
  
 
Regional disease 113 14.94 7.6 6.3 9.1 1.4 1.1 1.8 1.4 1.1 1.8 
 
Distant metastases 18 1.03 17.5 11.0 27.7 3.2 2.0 5.2 2.5 1.6 4.2 
  Unknown 170 22.67 7.5 6.5 8.7 1.4 1.1 1.8 1.2 1.0 1.6 
Active chemotherapyb Local disease 27 0.43 63.0 43.2 91.9 Reference   Reference   
 
Regional disease 38 0.74 51.3 37.3 70.5 0.8 0.5 1.3 0.8 0.5 1.2 
 
Distant metastases * * 26.2 6.6 104.8 0.4 0.1  1.7 0.3 0.1 1.4 
  Unknown 30 0.46 65.7 45.9 93.9 1.1 0.6 1.8 1.0 0.6 1.7 
Active surgeryc Local disease 26 0.92 28.1 19.2 41.3 Reference   Reference   
 
Regional disease 9 0.52 17.2 8.9 33.0 0.6 0.3 1.3 0.6 0.3 1.4 
 
Distant metastases * * 24.2 3.4 171.5 0.9 0.1 6.4 0.8 0.1 5.7 
  Unknown 14 0.65 21.5 12.7 36.3 0.8 0.4 1.5 0.7 0.4 1.4 
a Cohort time where participants are not at risk due to surgery or chemotherapy 
b During chemotherapy and for the 2 months following completion of therapy. Excludes person-time where participants are at risk following surgery. 
c During surgery and for the first 2 months following discharge from the surgical hospital admission. Excludes person-time where participants are at risk during or following chemotherapy.  
d Adjusted for grade, endocrine therapy, BMI, comorbidity (Charlson) and age. These variables were fitted using the same categorisation as in multivariable models presented in Table 2. 
* Number of outcome events and person-time are censored for cell frequencies <5 in line with CPRD policy 
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Table 4: Rates of VTE by surgery and chemotherapy 
 
    
Rate 
  
 
  Events Person-years (per 1,000 pys) 95% CI 
Baseline a 450 67,600 6.7 6.1 7.3 
      
Surgery onlyb During surgery hospitalisation  * * 12.2 3.1 48.9 
 
1st month following discharge 24 1,075 22.3 15.0 33.3 
 
2nd month following discharge 24 893 26.9 18.0 40.1 
 
3rd month following discharge 8 818 9.8 4.9 19.6 
       
Chemotherapy onlyc During chemotherapy 75 1,080 69.4 55.4 87.1 
 
1 month after chemotherapy 13 271 48.0 27.9 82.6 
 
2 months after chemotherapy 5 224 22.3 9.3 53.7 
 
3 months after chemotherapy * * 14.6 4.7 45.3 
       
Surgery and 
chemotherapy 
Chemotherapy during surgery 
recovery * * 9.4 2.4 37.6 
 
Surgeryd during chemotherapy 
recovery 5 54 92.1 38.3 221.2 
a Includes all cohort time aside for the time during (and 3 months following) chemotherapy and during the surgical hospital admission and 3 months following discharge. This includes the entire study time for 
women who did not undergo either chemotherapy or surgery.  
b Excludes time during (and 3 months following) chemotherapy 
c Excludes time whilst hospitalised for surgery and 3 months following discharge 
d Includes time during surgical admission and the 3 months following discharge 
* Number of outcome events and person-time are censored for cell frequencies <5 in line with CPRD policy 
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Table 5: Rates of VTE by type of endocrine therapy 
  
Events 
 
Person-years 
 
Rate per 1,000 person-years 
 
Univariable Cox model 
 
Multivariable Cox modele 
    95% CI HR 95% CI HR 95% CI 
Tamoxifen only (n=5,415)            
Before therapy 7 1,198 5.8    2.8 12.3 Reference Reference 
First 3 monthsa 30 1,246 24.1   16.8 34.4 4.1 1.8 9.4 5.5 2.3 12.7 
Subsequent time 159 30,453 5.2   4.5 6.1 1.1 0.5 2.9 1.9 0.9 4.3 
Aromatase inhibitors only (n=1,410)            
Before therapy 28 627 44.6  30.8 64.7 Reference Reference 
First 3 monthsa 9 318 28.3   14.7 54.3 0.6 0.3 1.3 0.8 0.5 1.4 
Subsequent time 46 4,697 9.8   7.3 13.1 0.2 0.1 0.4 0.3 0.2 0.5 
Tamoxifen followed by AIs (n=3,821)d            
Before Tamoxifen 18 1,121 16.1 10.1 25.5 Reference Reference 
First 3 months of Tamoxifenb 29 859 33.8 23.5 48.6 2.1 1.2 3.8 2.3 1.2 4.4 
Subsequent time for Tamoxifenb 97 8,812 11.0 9.0 13.4 0.7 0.4 1.1 1.1 0.6 2.0 
First 3 months of AIs 10 852 11.7 6.3 21.8 0.7 0.3 1.6 1.0 0.4 2.4 
Subsequent time for AIsc 78 11,509 6.8 5.4 8.5 0.4 0.2 0.7 0.6 0.3 1.2 
a 3 months from day of the first Tamoxifen/AI prescription following cancer diagnosis 
b Exposure period ceases on the day in which patients switch to AI (if applicable) 
c Cohort time starting 3 months after commencing AIs until the completion of follow-up 
d An equivalent analysis was not presented for the 233 women (12 VTE events) who switched from AIs to Tamoxifen as this number was too small for a meaningful analysis.   
e Adjusted for stage, grade, surgery, chemotherapy, BMI, comorbidity (Charlson) and age. These variables were fitted using the same categorisation as in multivariable models presented in Table 2. 
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Figure 1: Rates of VTE around chemotherapy 
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